Alpha 2.0
Login Register
» Authors » Michael A Derby

Michael A Derby

Explore the profile of Michael A Derby including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 167
Followers 0
Related Specialty
Pharmacology
Top 10 Co-Authors
Mauricio Maia
Jorge A Tavel
Rong Deng
Tracy Burgess
Jeremy J Lim
Priscilla Horn
Elizabeth Newton
Jacqueline M McBride
Carrie M Rosenberger
Maikke B Ohlson
Published In
Antimicrob Agents Chemother
J Cardiovasc Pharmacol
Clin Pharmacokinet
Affiliations
Soon will be listed here.
Recent Articles
1.
Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat"
McBride J, Lim J, Burgess T, Deng R, Derby M, Maia M, et al.
Antimicrob Agents Chemother . 2017 Dec; 62(1). PMID: 29269431
No abstract available.
2.
Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model
McBride J, Lim J, Burgess T, Deng R, Derby M, Maia M, et al.
Antimicrob Agents Chemother . 2017 Aug; 61(11). PMID: 28807912
MHAA4549A, a human monoclonal antibody targeting the hemagglutinin stalk region of influenza A virus (IAV), is being developed as a therapeutic for patients hospitalized with severe IAV infection. The safety...
3.
Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial
Deng R, Lee A, Maia M, Lim J, Burgess T, Horn P, et al.
Clin Pharmacokinet . 2017 Jun; 57(3):367-377. PMID: 28639229
Background And Objectives: MHAA4549A, a human anti-influenza immunoglobulin (Ig) G1 monoclonal antibody, is being developed to treat patients hospitalized for influenza A infection. This study examined the pharmacokinetics (PKs) of...
4.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers
Lim J, Derby M, Zhang Y, Deng R, Larouche R, Anderson M, et al.
Antimicrob Agents Chemother . 2017 Jun; 61(8). PMID: 28559255
Influenza B can cause significant morbidity and mortality. MHAB5553A, a human monoclonal immunoglobulin G1 (IgG1) antibody that binds to a highly conserved region of the hemagglutinin protein of influenza B...
5.
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
Ishida J, Patel A, Mehta A, Gatault P, McBride J, Burgess T, et al.
Antimicrob Agents Chemother . 2016 Nov; 61(2). PMID: 27872061
Cytomegalovirus (CMV) infection is a significant complication after kidney transplantation. We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent CMV infection in high-risk kidney transplant...
6.
Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers
Lim J, Deng R, Derby M, Larouche R, Horn P, Anderson M, et al.
Antimicrob Agents Chemother . 2016 Jul; 60(9):5437-44. PMID: 27381392
Hospitalized patients with severe influenza are at significant risk for morbidity and mortality. MHAA4549A is a human monoclonal immunoglobulin (Ig) G1 antibody that binds to a highly conserved stalk region...
7.
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults
Ishida J, Burgess T, Derby M, Brown P, Maia M, Deng R, et al.
Antimicrob Agents Chemother . 2015 Jun; 59(8):4919-29. PMID: 26055360
Cytomegalovirus can cause debilitating and life-threatening disease in newborns infected in utero and immunocompromised individuals, including transplant recipients. RG7667 is a unique combination of two monoclonal antibodies that binds glycoprotein...
8.
The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate
Derby M, Zhang L, Chappell J, Gonzales C, Callaghan J, Leibowitz M, et al.
J Cardiovasc Pharmacol . 2007 Jun; 49(6):384-93. PMID: 17577103
The effects of supratherapeutic dosages of duloxetine, a serotonin and norepinephrine reuptake inhibitor, on blood pressure and pulse rate were assessed in a multicenter, double-blind, randomized, placebo-controlled, crossover study in...